- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05510999
The Efficacy of Graminex® Flower Pollen Extracts in Healthy Women With Urinary Incontinence
A Randomized, Double-blind, Placebo-controlled, Study to Investigate the Efficacy of Graminex® Flower Pollen Extracts in Healthy Women With Urinary Incontinence.
Study Overview
Status
Conditions
Intervention / Treatment
- Other: Placebo
- Dietary supplement: Water soluble pollen extract fraction
- Dietary supplement: Lipid soluble pollen extract fraction + water soluble pollen extract fraction
- Dietary supplement: Lipid soluble pollen extract fraction
- Dietary supplement: Water soluble pollen extract fraction + cranberry powder
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 5R8
- KGK Science Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females between the ages of 40-75 inclusive.
- BMI 18.5 kg/m2 - 34.9 kg/m2 inclusive.
- Involuntary loss of urine (incontinence) persisting for at least 1 month as determined by a score ≥ 5 on the ICIQ-SF questionnaire at the screening visit.
Female participant is not of child-bearing potential, defined as females who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation) or have been post-menopausal (natural or surgically) for at least 1 year prior to screening.
Or,
Females of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Agree to keep lifestyle habits consistent (dietary habits and physical activity patterns) for the duration of the trial.
- Willing to maintain current caffeine intake. Individuals with excessive habitual caffeine intake (>3 cups coffee or >4 cups caffeinated tea per day or >2 energy drinks) will be required to reduce consumption for 2 weeks prior to baseline.
- Healthy as determined by laboratory results, medical history, and physical exam.
- Has given voluntary, written, informed consent to participate in the study.
Exclusion Criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial.
- Allergy or sensitivity to test product ingredients.
- Treatment (ie. pessary) or surgery (ie. sling, mesh) for urinary incontinence from a continence specialist (ie. urologist, urogynecologist, gynecologist) within the past 5 years.
- Treatment for overactive or neurogenic bladder in previous 3 months (ie. neuromodulation, botox).
- Initiation of pelvic floor therapy in the previous 3 months.
- Current utilization of a catheter for urination.
- Current urinary tract infection (UTI, confirmed by laboratory analysis), verbal confirmation of infection in previous 3 months or history of recurrent UTIs.
- Women who are currently taking medications for urinary incontinence/overactive bladder (see Section 6.3.1).
- Irregular menstrual periods within the previous 6 months (less than 21 or greater than 33 days between cycles).
- Women who are within 1-year postpartum.
- Genital malformation (i.e. Vaginal fistula) or vaginal and/or vulvar disorder (i.e. vulvovaginal atrophy).
- Women on hormone replacement therapy (oral or topical), unless on a stable dose for ≥6 months.
- Metal implants that may affect the DXA scan results will be assessed on case-by-case basis by the QI.
- Current, chronic constipation reviewed on a case-by-case basis by the QI.
- Current or history of diabetes.
- Current or history of bladder tumour.
- Current sexually transmitted infection (confirmed by laboratory analysis), or verbal confirmation of infection in previous 3 months.
- Current or history of liver, kidney or heart disease.
- Current or pre-existing unstable thyroid condition. Treatment on a stable dose of medication for over one year will be reviewed on a case-by-case basis by the QI .
- Current or history of bleeding disorders.
- Clinically significant abnormal laboratory results at screening.
- Excessive consumption of alcohol equivalent to >2 alcoholic drinks/day (average).
- Alcohol or drug abuse within the last 6 months.
- Individuals who are cognitively impaired and/or who are unable to give informed consent.
- Any autoimmune disease or immune-compromised (i.e. HIV positive, use of anti-rejection medication, rheumatoid arthritis, Hepatitis B/C positive).
- Participation in other clinical research trials one month prior to or during enrollment will be assessed case-by-case by the QI.
- Any other condition, that, in the opinion of the QI, may adversely affect the participant's ability to provide written informed consent and complete the study or its measures, or pose significant risk to the participant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit.
If a dose is missed participants are instructed to take the missed dose with the next scheduled dose.
Participants will be advised not to exceed 3 capsules daily.
|
One capsule of placebo will be taken twice daily for 24 weeks.
|
Experimental: Water soluble pollen extract fraction
The experimental product contains 180mg (360mg/day) of water soluble pollen extract fraction.
Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit.
If a dose is missed participants are instructed to take the missed dose with the next scheduled dose.
Participants will be advised not to exceed 3 capsules daily.
|
Each capsule contains 180 mg of water soluble pollen extract fraction.
One capsule will be taken twice daily (360 mg/day) for 24 weeks.
|
Experimental: Lipid soluble pollen extract fraction + water soluble pollen extract fraction
The experimental product is a combination of 9 mg lipid soluble pollen extract fraction (18mg/day) and 180 mg water soluble pollen extract fraction (360mg/day).
Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit.
If a dose is missed participants are instructed to take the missed dose with the next scheduled dose.
Participants will be advised not to exceed 3 capsules daily.
|
Each capsule contains a combination of 9 mg of lipid soluble pollen extract fraction and 180 mg of water soluble pollen extract fraction.
One capsule will be taken twice daily (18 mg/day and 360 mg/day, respectively) for 24 weeks.
|
Experimental: Lipid soluble pollen extract fraction
The experimental product contains 9mg (18mg/day) of lipid soluble pollen extract fraction.
Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit.
If a dose is missed participants are instructed to take the missed dose with the next scheduled dose.
Participants will be advised not to exceed 3 capsules daily.
|
Each capsule contains 9 mg of lipid soluble pollen extract fraction.
One capsule of will be taken twice daily (18 mg/day) for 24 weeks.
|
Experimental: Water soluble pollen extract fraction + cranberry powder
The experimental product is a combination of 42 mg water soluble pollen extract fraction (84 mg/day) and 125 mg cranberry powder (250 mg/day).
Participants will be instructed to take one (1) capsule twice daily before breakfast and dinner with a glass of water for 24 weeks beginning on the Day 1, the day after their baseline visit.
If a dose is missed participants are instructed to take the missed dose with the next scheduled dose.
Participants will be advised not to exceed 3 capsules daily.
|
Each capsule contains a combination of 42 mg of water soluble pollen extract and 125 mg of cranberry powder.
One capsule will be taken twice daily (84 mg/day and 250 mg/day, respectively) for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in severity of urinary incontinence between baseline and 24 weeks.
Time Frame: baseline and 24 weeks
|
The change in severity of urinary incontinence between baseline and 24 weeks as assessed by the ICIQ-SF will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline and 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in severity of urinary incontinence between baseline and week 6, 12, and 18.
Time Frame: baseline, week 6, week 12, week 18
|
The change in severity of urinary incontinence between baseline and week 6, 12, and 18 as assessed by the ICIQ-SF will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18
|
The change in frequency of urinary incontinence between baseline and week 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in frequency of urinary incontinence between baseline and week 6, 12, 18, and 24 as assessed by void diary will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in daily urinary leakage volume between baseline and week 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in daily urinary leakage volume between baseline and week 6, 12, 18, and 24 as assessed by 24-hour pad weight will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in stress-induced urinary leakage volume between baseline and week 24.
Time Frame: baseline, week 24
|
The change in stress-induced urinary leakage volume between baseline and week 24 as assessed by pad weight following a provocative maneuvers challenge will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 24
|
The change in frequency of nocturia between baseline and week 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in frequency of nocturia between baseline and week 6, 12, 18, and 24 as assessed by void diary will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in frequency of daytime urination between baseline and week 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in frequency of daytime urination between baseline and week 6, 12, 18, and 24 as assessed by void diary will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in bone density between baseline and week 24.
Time Frame: baseline, week 24
|
The change in frequency of bone density between baseline and week 24 as assessed by DXA scan will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 24
|
The change in incontinence-related quality of life between baseline and weeks 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in incontinence-related quality of life between baseline and weeks 6, 12, 18, and 24 as assessed by I-QoL will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in degree of bother between baseline and weeks 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in degree of bother between baseline and weeks 6, 12, 18, and 24 as assessed by OAB-q will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in sleep quality between baseline and weeks 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in sleep quality between baseline and weeks 6, 12, 18, and 24 as assessed by Sleep Index will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The change in Lower Urinary Tract Symptom Score (LUTSS) between baseline and weeks 6, 12, 18, and 24.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
The change in Lower Urinary Tract Symptom Score (LUTSS) between baseline and weeks 6, 12, 18, and 24 as assessed by the LUTSS Questionnaire will be compared between groups assigned to the Graminex® Flower Pollen Extracts and placebo.
|
baseline, week 6, week 12, week 18, week 24
|
The incidence of pre-emergent and post-emergent adverse events during a 24-week supplementation period.
Time Frame: 24 weeks
|
24 weeks
|
|
Vital sign measurements (blood pressure; BP) during a 24-week supplementation period.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
baseline, week 6, week 12, week 18, week 24
|
|
Vital sign measurements (heart rate; HR) during a 24-week supplementation period.
Time Frame: baseline, week 6, week 12, week 18, week 24
|
baseline, week 6, week 12, week 18, week 24
|
|
Aspartate aminotransferase (AST) measurement following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including aspartate aminotransferase (AST)) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Alanine aminotransferase (ALT) measurement following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including alanine aminotransferase (ALT)) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Bilirubin measurement following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including bilirubin) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Creatinine measurement following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including creatinine) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Measurement of electrolytes following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including electrolytes (Na, K, Cl,)) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Estimated glomerular filtration rate (eGFR) measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Clinical chemistry (including estimated glomerular filtration rate (eGFR)) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
White blood cell measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Hematology measurements (including white blood cell count with differential (neutrophils, lymphocytes, monocytes, eosinophils, basophils) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Red blood cell measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Hematology measurements (including red blood cell count) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Hemoglobin measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Hematology measurements (including hemoglobin) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Hematocrit measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Hematology measurements (including hematocrit) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Platelet count measurements following a 24-week supplementation.
Time Frame: 24 weeks
|
Hematology measurements (including platelet count) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Mean corpuscular hemoglobin following a 24-week supplementation.
Time Frame: 24 weeks
|
Red blood cell indices (including mean corpuscular hemoglobin) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Mean corpuscular hemoglobin concentration following a 24-week supplementation.
Time Frame: 24 weeks
|
Red blood cell indices (including mean corpuscular hemoglobin concentration) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Mean corpuscular volume following a 24-week supplementation.
Time Frame: 24 weeks
|
Red blood cell indices (including mean corpuscular volume) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Red cell distribution width following a 24-week supplementation.
Time Frame: 24 weeks
|
Red blood cell indices (including red cell distribution width) will be measured in blood from study participants at 24 weeks.
|
24 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Crowley, KGK Science Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19GUHG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Incontinence
-
University of New MexicoRecruitingUrinary Incontinence | Urge Incontinence | Stress Incontinence, FemaleUnited States
-
Juna d.o.o.CompletedFemale Stress Urinary Incontinence | Mixed Incontinence, Urge and Stress
-
University of California, San FranciscoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Stanford...CompletedUrinary Incontinence, Stress | Urge Incontinence | Urinary Stress Incontinence | Stress Incontinence, Urinary | Stress Incontinence | Stress Incontinence, Female | Urgency UrinaryUnited States
-
Ludwig-Maximilians - University of MunichUnknownIncontinence, Overactive Bladder, Stress Urinary IncontinenceGermany
-
San Diego Sexual MedicineRecruitingStress Urinary Incontinence | Urge IncontinenceUnited States
-
Far Eastern Memorial HospitalRecruitingWomen With Stress Urinary IncontinenceTaiwan
-
Copenhagen University Hospital at HerlevZealand University HospitalTerminatedStress Urinary Incontinence | Urge Urinary IncontinenceDenmark
-
ScitonCompletedUrinary Incontinence | Stress Urinary Incontinence | Urge IncontinenceUnited States
-
Université de SherbrookeRecruitingUrinary Incontinence | Urinary Stress Incontinence | Post-Prostatectomy Incontinence | Stress Incontinence, MaleCanada
-
University of ZurichCompletedStress Urinary Incontinence | Urge Urinary Incontinence
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States